Last reviewed · How we verify
Carcinoma of female breast
Approved treatments
- Teolit
- adriacin · Chipscreen Biosciences, Ltd.
- Hydroxydaunorubicin · University of Colorado, Denver
- Vinblastin · The Lymphoma Academic Research Organisation
- Lentaron
- Liposomal Doxorubicin · Pfizer
- Doxorubicin Hydrochloride · Pfizer
Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division. - Trexall · Generic (originally Lederle Laboratories)
Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune). - Methotrexat · Biocad
- Nolvadex · AstraZeneca (originally ICI)
Selective estrogen receptor modulator (SERM) that blocks estrogen signaling in breast tissue while preserving bone density. - Hydroxydaunomycin · Weill Medical College of Cornell University
- Adriamycin · Johann Wolfgang Goethe University Hospital
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Carcinoma of female breast patent landscape — cliff calendar, originator estates, attackable patents
- Carcinoma of female breast treatment landscape brief
- Carcinoma of female breast treatment updates RSS
Frequently asked questions about Carcinoma of female breast
What drugs treat Carcinoma of female breast?
Tracked treatments include Teolit, adriacin, Hydroxydaunorubicin, Vinblastin, Lentaron, Liposomal Doxorubicin, Doxorubicin Hydrochloride, Trexall.
What is the treatment for Carcinoma of female breast?
Standard treatment for Carcinoma of female breast includes Teolit, adriacin, Hydroxydaunorubicin, Vinblastin, Lentaron. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Carcinoma of female breast patent cliff · Carcinoma of female breast CI report
- Treatment: Teolit
- Treatment: adriacin · Chipscreen Biosciences, Ltd.
- Treatment: Hydroxydaunorubicin · University of Colorado, Denver
- Treatment: Vinblastin · The Lymphoma Academic Research Organisation
- Treatment: Lentaron
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing